Trazodone hydrochloride

Discontinued Product

6336 has been discontinued.

View all 5-HT<sub>2A</sub> Receptors products.
Description: 5-HT2A and α1 adrenoceptor antagonist; also enhances neural differentiation; antidepressant and neuroprotectant
Chemical Name: 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (3)

Biological Activity for Trazodone hydrochloride

Trazodone hydrochloride is a 5-HT2A and α1 adrenoceptor antagonist. Enhances neuronal differentiation of mouse and human neural progenitor cells. Also inhibits PERK/eIF2α-P-mediated reduction in protein synthesis and restores memory deficits in a mouse dementia model. Antidepressant and neuroprotectant.

Compound Libraries for Trazodone hydrochloride

Trazodone hydrochloride is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen FDA-Approved Drugs and Tocriscreen Stem Cell Library. Find out more about compound libraries available from Tocris.

Technical Data for Trazodone hydrochloride

M. Wt 408.32
Formula C19H22ClN5O.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 25332-39-2
PubChem ID 62935
InChI Key OHHDIOKRWWOXMT-UHFFFAOYSA-N
Smiles ClC1=CC=CC(N2CCN(CC2)CCCN3N=C4C=CC=CN4C3=O)=C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Trazodone hydrochloride

References for Trazodone hydrochloride

References are publications that support the biological activity of the product.

Bortolotto et al (2017) Proneurogenic effects of traz. in murine and human neural progenitor cells. ACS Chem.Neurosci. 8 2027 PMID: 28636360

Halliday et al (2017) Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain 140 1768 PMID: 28430857

View Related Products by Product Action

View all 5-HT2A Receptor Antagonists

Keywords: Trazodone hydrochloride, Trazodone hydrochloride supplier, 5-HT2A, alpha1, a1, α1, adrenoceptor, antagonist, antagonism, neuronal, differentiation, antidepressant, depression, neuroprotection, neuroprotectant, eIF2alpha, eIF2a, eIF2α, inhibitors, inhibits, Receptors, Adrenergic, Alpha-1, Neural, Stem, Cells, PERK, 6336, Tocris Bioscience

Citations for Trazodone hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for Trazodone hydrochloride.

Reviews for Trazodone hydrochloride

There are currently no reviews for this product. Be the first to review Trazodone hydrochloride and earn rewards!

Have you used Trazodone hydrochloride?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.